These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1821193)

  • 1. Sequential observation of fundus changes in patients with long standing membranoproliferative glomerulonephritis type II (MPGN type II).
    Leys A; Vanrenterghem Y; Van Damme B; Snyers B; Pirson Y; Leys M
    Eur J Ophthalmol; 1991; 1(1):17-22. PubMed ID: 1821193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fundus changes in type III membranoproliferative glomerulonephritis: a case report.
    Takei M; Obana A; Inomata T; Tanaka T; Shiang T; Bae Y; Takemura T; Murakami A
    BMC Ophthalmol; 2018 Mar; 18(1):72. PubMed ID: 29510686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fundus changes in membranoproliferative glomerulonephritis type II. A fluorescein angiographic study of 23 patients.
    Leys A; Vanrenterghem Y; Van Damme B; Snyers B; Pirson Y; Leys M
    Graefes Arch Clin Exp Ophthalmol; 1991; 229(5):406-10. PubMed ID: 1937071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membranoproliferative glomerulonephritis type II associated with central serous retinopathy.
    Ulbig MR; Riordan-Eva P; Holz FG; Rees HC; Hamilton PA
    Am J Ophthalmol; 1993 Oct; 116(4):410-3. PubMed ID: 8213970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subretinal neovascular membranes in membranoproliferative glomerulonephritis type II].
    Framme C; Herboth T; Roider J; Laqua H
    Klin Monbl Augenheilkd; 1998 Oct; 213(4):252-3. PubMed ID: 9848073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ocular impairment during type II membranoproliferative glomerulonephritis].
    Lahbil D; Rais L; Hamdani M; El Kettani A; Laouissi N; Zaghloul K; Amraoui A
    J Fr Ophtalmol; 2002 Nov; 25(9):949-54. PubMed ID: 12515943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHEDDING LIGHT ON FUNDUS DRUSEN ASSOCIATED WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: BREAKING STEREOTYPES OF TYPES I, II, AND III.
    Dalvin LA; Fervenza FC; Sethi S; Pulido JS
    Retin Cases Brief Rep; 2016; 10(1):72-8. PubMed ID: 26110522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of choroidal neovascularisation secondary to membranoproliferative glomerulonephritis type II with intravitreal ranibizumab.
    McCullagh D; Silvestri G; Maxwell AP
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24895384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optical coherence tomography of fundus abnormalities associated with type II membranoproliferative glomerulonephritis.
    Batioğlu F; Müftüoğlu O; Atmaca L
    Retina; 2003 Apr; 23(2):261-2. PubMed ID: 12707615
    [No Abstract]   [Full Text] [Related]  

  • 10. [Choroidal neovascularisation in type II membranoproliferative glomerulonephritis, photodynamic therapy as a treatment option--a case report].
    Hassenstein A; Richard G
    Klin Monbl Augenheilkd; 2003 Jul; 220(7):492-5. PubMed ID: 12886510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subretinal neovascular membranes associated with chronic membranoproliferative glomerulonephritis type II.
    Leys A; Michielsen B; Leys M; Vanrenterghem Y; Missotten L; Van Damme B
    Graefes Arch Clin Exp Ophthalmol; 1990; 228(6):499-504. PubMed ID: 2265764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of drusen-like lesions in patients with type II mesangiocapillary glomerulonephritis.
    D'souza Y; Short CD; McLeod D; Bonshek RE
    Br J Ophthalmol; 2008 Jul; 92(7):950-3. PubMed ID: 18577648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fundus changes in chronic membranoproliferative glomerulonephritis type II.
    Michielsen B; Leys A; Van Damme B; Missotten L
    Doc Ophthalmol; 1990-1991; 76(3):219-29. PubMed ID: 2103524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific eye fundus lesions in type II membranoproliferative glomerulonephritis.
    Leys A; Proesmans W; Van Damme-Lombaerts R; Van Damme B
    Pediatr Nephrol; 1991 Mar; 5(2):189-92. PubMed ID: 2031833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal function abnormalities in membranoproliferative glomerulonephritis type II.
    Kim RY; Faktorovich EG; Kuo CY; Olson JL
    Am J Ophthalmol; 1997 May; 123(5):619-28. PubMed ID: 9152067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microperimetric evaluation of macula in retinopathy of membranoproliferative glomerulonephritis type II: a case report.
    Shenoy R; McCilvenny S
    Eur J Ophthalmol; 2006; 16(4):634-6. PubMed ID: 16952110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiology of type II mesangiocapillary glomerulonephritis with associated fundus abnormalities.
    O'Brien C; Duvall-Young J; Brown M; Short C; Bone M
    Br J Ophthalmol; 1993 Dec; 77(12):778-80. PubMed ID: 8110672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manifestations of Complement-Mediated and Immune Complex-Mediated Membranoproliferative Glomerulonephritis: A Comparative Consecutive Series.
    Dalvin LA; Fervenza FC; Sethi S; Pulido JS
    Ophthalmology; 2016 Jul; 123(7):1588-94. PubMed ID: 26996341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Choroidal Neovascularization Prevention Trial Research Group.
    Ophthalmology; 1998 Jan; 105(1):11-23. PubMed ID: 9442774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posterior segment changes in membranoproliferative glomerulonephritis.
    Kim DD; Mieler WF; Wolf MD
    Am J Ophthalmol; 1992 Nov; 114(5):593-9. PubMed ID: 1443022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.